Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenström Macroglobulinemia
MeSH terms: Burkitt Lymphoma; Mycoses; Lymphoma; Leukemia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Mycosis Fungoides; Sezary Syndrome; Leukemia, T-Cell; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Large-Cell, Anaplastic; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Lymphoma, Extranodal NK-T-Cell; Intraocular Lymphoma; Leukemia, Large Granular Lymphocytic; Immunoblastic Lymphadenopathy; Recurrence
Intervention: indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation
Intervention description: Given IV; Given IV; Undergo autologous peripheral blood stem cell transplant
Intervention MeSH terms: Antineoplastic Agents, Immunological; Antibodies; Immunoglobulins; Antibodies, Monoclonal
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 2.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase I trial studies the side effects and best dose of monoclonal antibody therapy
      before stem cell transplant in treating patients with relapsed or refractory lymphoid
      malignancies. Radiolabeled monoclonal antibodies, such as yttrium-90 anti-CD45 monoclonal
      antibody BC8, can find cancer cells and carry cancer-killing substances to them without
      harming normal cells. When the healthy stem cells from a donor are infused into the patient
      they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,
      and platelets. Giving radiolabeled monoclonal antibody before a stem cell transplant may be
      an effective treatment for relapsed or refractory lymphoid malignancies.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of B-NHL, T-NHL, or HL; only
             patients with classical HL must have documented histologic demonstration of CD45+
             cells adjacent to the Reed Sternberg cells; patients must have received at least one
             prior standard systemic therapy with documented recurrent or refractory disease;
             patients with mantle cell lymphoma (MCL), T-NHL, or other high-risk malignancies may
             be enrolled/transplanted in complete remission (CR)/first partial remission (PR1)

          -  Creatinine < 2.0

          -  Bilirubin < 1.5 mg/dL

          -  All patients eligible for therapeutic study must have a minimum of >= 2 x 10^6 CD34/kg
             autologous hematopoietic stem cells harvested and cryopreserved

          -  Patients must have an expected survival of > 60 days and must be free of major
             infection

          -  Patients are preferred to have either a tumor mass amenable to core needle biopsy
             during the dosimetry phase, or a measurable tumor mass with at least one site of
             involvement measuring 2.5 cm in largest dimension on computed tomography (CT) imaging
             for purposes of planar and/or single-photon emission computed tomography (SPECT)/CT
             tumor dosimetry

        Exclusion Criteria:

          -  Circulating human anti-mouse antibody (HAMA), to be determined before each infusion

          -  Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled
             therapy dose with the exception of rituximab

          -  Inability to understand or give an informed consent

          -  Lymphoma involving the central nervous system

          -  Other serious medical conditions considered to represent contraindications to ASCT
             (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of the lung
             for carbon monoxide [DLCO] < 50% predicted, acquired immune deficiency syndrome
             [AIDS], etc.)

          -  Known human immunodeficiency virus (HIV) seropositivity

          -  Pregnancy or breast feeding

          -  Prior allogeneic bone marrow or stem cell transplant

          -  Prior autologous bone marrow or stem cell transplant within 1 year of enrollment

          -  Prior radiation therapy (RT) > 20 Gray (Gy) to a critical organ within 1 year of
             enrollment

          -  Southwest Oncology Group (SWOG) performance status >= 2.0

          -  Patients with relapsed diffuse large B-cell lymphoma (DLBCL) or HL that have achieved
             a positron emission tomography (PET)-negative CR following first salvage chemotherapy